NYSE:SYK Stryker (SYK) Stock Price, News & Analysis $363.76 +2.40 (+0.66%) (As of 11:45 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Stryker Stock (NYSE:SYK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$362.62▼$365.7050-Day Range$315.94▼$371.9752-Week Range$249.98▼$374.63Volume249,423 shsAverage Volume1.28 million shsMarket Capitalization$138.62 billionP/E Ratio41.53Dividend Yield0.88%Price Target$378.58Consensus RatingModerate Buy Company OverviewStryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.Read More… Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Stryker Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 92nd PercentileStryker scored higher than 92% of companies evaluated by MarketBeat, and ranked 89th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingStryker has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 15 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageStryker has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Stryker's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth12.08% Earnings GrowthEarnings for Stryker are expected to grow by 12.08% in the coming year, from $12.00 to $13.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stryker is 41.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.51.Price to Earnings Ratio vs. SectorThe P/E ratio of Stryker is 41.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 147.31.Price to Earnings Growth RatioStryker has a PEG Ratio of 2.87. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioStryker has a P/B Ratio of 7.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Stryker's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.24% of the float of Stryker has been sold short.Short Interest Ratio / Days to CoverStryker has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Stryker has recently increased by 18.67%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldStryker has a dividend yield of 0.86%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthStryker does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Stryker is 36.53%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Stryker will have a dividend payout ratio of 23.79% next year. This indicates that Stryker will be able to sustain or increase its dividend.Read more about Stryker's dividend. Sustainability and ESG4.2 / 5Environmental Score-0.95 Percentage of Shares Shorted1.24% of the float of Stryker has been sold short.Short Interest Ratio / Days to CoverStryker has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Stryker has recently increased by 18.67%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.49 News SentimentStryker has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Stryker this week, compared to 12 articles on an average week.Search InterestOnly 8 people have searched for SYK on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Stryker to their MarketBeat watchlist in the last 30 days. This is a decrease of -69% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Stryker insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $71,811,372.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Stryker is held by insiders.Percentage Held by Institutions77.09% of the stock of Stryker is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Stryker's insider trading history. SYK Stock News HeadlinesInsider Selling: Stryker Co. (NYSE:SYK) VP Sells 2,121 Shares of StockSeptember 18 at 5:22 AM | insidertrades.comStryker Co. (NYSE:SYK) VP Sells $2,696,202.06 in StockSeptember 18 at 5:22 AM | insidertrades.comCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. September 19, 2024 | True Gold Republic (Ad)Boston Scientific: Why This MedTech Giant Isn’t Slowing Down (SYK)Boston Scientific Co (NYSE: BSX) is a global medical device manufacturer that’s seeing a strong influx of investors as shares grind to new all-time highs.September 17 at 8:00 AM | marketbeat.comMedtronic Stock: Growth On Rise of the Cardiovascular Machines (SYK)Medtronic is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseasesSeptember 9, 2024 | marketbeat.comM Kathryn Fink Sells 2,121 Shares of Stryker Co. (NYSE:SYK) StockSeptember 19 at 6:05 AM | americanbankingnews.comM Kathryn Fink Sells 7,347 Shares of Stryker Co. (NYSE:SYK) StockSeptember 19 at 4:30 AM | americanbankingnews.comStryker executive sells over $3.4 million in company stockSeptember 18 at 8:16 AM | in.investing.comSee More Headlines SYK Stock Analysis - Frequently Asked Questions How have SYK shares performed this year? Stryker's stock was trading at $299.46 at the beginning of 2024. Since then, SYK stock has increased by 21.6% and is now trading at $364.17. View the best growth stocks for 2024 here. How were Stryker's earnings last quarter? Stryker Co. (NYSE:SYK) posted its quarterly earnings data on Tuesday, July, 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.79 by $0.02. Stryker's revenue for the quarter was up 8.5% compared to the same quarter last year. Read the conference call transcript. Does Stryker have any subsidiaries? Stryker subsidiaries include these companies: Vocera Communications, Vocera, Gauss Surgical, OrthoSensor, Wright Medical Group, Cardan Robotics, Mobius Imaging, and more. Who are Stryker's major shareholders? Stryker's top institutional shareholders include Bank of New York Mellon Corp (1.49%), First Western Trust Bank (0.92%), Legal & General Group Plc (0.75%) and Clearbridge Investments LLC (0.61%). Insiders that own company stock include Ronda E Stryker, Kevin Lobo, James Andrew Pierce, Allan C Golston, M Kathryn Fink, Viju Menon, Robert S Fletcher, Srikant M Datar, William E Berry Jr and Glenn S Boehnlein. View institutional ownership trends. How do I buy shares of Stryker? Shares of SYK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Stryker own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stryker investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), Home Depot (HD), Medtronic (MDT), Visa (V), AbbVie (ABBV) and Cisco Systems (CSCO). Company Calendar Ex-Dividend for 7/31 Dividend6/28/2024Last Earnings7/30/2024Dividend Payable7/31/2024Today9/19/2024Ex-Dividend for 10/31 Dividend9/30/2024Dividend Payable10/31/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNYSE:SYK CUSIP86366710 CIK310764 Webwww.strykercorp.com Phone(269) 385-2600Fax269-385-1062Employees52,000Year Founded1941Price Target and Rating Average Stock Price Target$378.58 High Stock Price Target$406.00 Low Stock Price Target$345.00 Potential Upside/Downside+4.3%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)$8.76 Trailing P/E Ratio41.44 Forward P/E Ratio30.25 P/E Growth2.87Net Income$3.17 billion Net Margins16.12% Pretax Margin18.78% Return on Equity22.89% Return on Assets11.03% Debt Debt-to-Equity Ratio0.51 Current Ratio1.68 Quick Ratio0.95 Sales & Book Value Annual Sales$20.50 billion Price / Sales6.75 Cash Flow$13.09 per share Price / Cash Flow27.74 Book Value$48.94 per share Price / Book7.42Miscellaneous Outstanding Shares381,080,000Free Float358,474,000Market Cap$138.33 billion OptionableOptionable Beta0.91 Social Links Should I Buy Stryker Stock? SYK Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 4, 2024. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com. Stryker Bull Case Here are some ways that investors could benefit from investing in Stryker Co.: Stryker Co. has consistently shown strong financial performance with a solid return on equity of 22.89%, indicating efficient use of shareholder funds. The company has a diverse product portfolio across its MedSurg, Neurotechnology, and Orthopaedics and Spine segments, reducing dependency on any single market. Recent insider selling activities, including the CFO selling shares at $333.00, could indicate confidence in the company's future performance. Stryker Co. announced a quarterly dividend of $0.80 per share, reflecting a stable dividend payout ratio of 36.53% and a yield of 0.89% for investors seeking income. Analysts have given Stryker Co. an average rating of "Moderate Buy" with a target price of $373.84, suggesting potential upside for investors based on market expectations. Stryker Bear Case Investors should be bearish about investing in Stryker Co. for these reasons: The recent insider selling activities, with insiders selling a significant number of shares, may raise concerns about the company's future growth prospects. Stryker Co.'s stock price has been relatively stagnant, trading down 0.2% recently, which could indicate limited short-term price appreciation potential. The company's P/E ratio of 41.14 and price-to-earnings-growth ratio of 2.78 suggest that the stock may be currently overvalued compared to its growth prospects. While the company has a strong market capitalization of $137.35 billion, the beta of 0.89 indicates that the stock may be less volatile than the market average, potentially limiting potential returns for risk-seeking investors. Despite positive earnings results, Stryker Co. faces competition in the medical technology sector, which could impact its market share and profitability in the long term. This page (NYSE:SYK) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall St...Chaikin Analytics | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Stryker Co. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Stryker With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.